Natera told investors it has submitted its Latitude tissue‑free minimal residual disease (MRD) test for MolDx assessment in colorectal cancer and has multiple Signatera submissions under review, actions the company expects will expand Medicare coverage and drive adoption in 2026. Management highlighted sequential improvements in average selling prices (ASP) during 2025 and said broader reimbursement could materially lift volumes and ASPs. CEO Steve Chapman and President John Fesko quantified upside: addressing currently non‑covered indications could add “a couple hundred million” dollars in gross profit, and the company plans validation in additional cancer types later in 2026. Natera also reported growing commercial payer coverage and continued investment in clinical trials and technology development across the MRD portfolio. Payers’ MolDx decisions and commercial coverage trajectories will determine the timing and scale of the anticipated revenue upside.